Accelrys (NASDAQ:ACCL), a leading scientific enterprise R&D software and services company, supports industries and organizations that rely on scientific innovation to differentiate themselves. Accelrys’ Enterprise R&D Architecture, built on the industry leading Pipeline Pilot™ platform, enables customers to access, organize, analyze and share scientific data in unprecedented ways, ultimately enhancing innovation, improving productivity and compliance, reducing costs and speeding time from lab to market.
Global Research develops breakthrough innovations in areas such as medical imaging, energy generation technology, jet engines and lighting. Our diverse set of technology expertise ranges from electronics to chemistry, biosciences to computing, metallurgy to fluid mechanics, materials to imaging– and everything in between.
Baxter International Inc. is a global healthcare company that, through its subsidiaries assists healthcare professionals and their patients with treatment of complex medical conditions including hemophilia, immune disorders, kidney disease, trauma and other conditions.
Merrimack Pharmaceuticals are dedicated to the discovery and development of innovative therapies for the treatment of autoimmune disease and cancer. Merrimack is advancing a robust pipeline of clinical and early-stage biologics that represent the next generation of patient-directed, targeted therapies.
3DM Inc. is a privately-held specialty biomaterials company, with a mission of developing novel medical therapies through its technologies for accelerating wound healing and tissue regeneration across a range of medical indications.
3DM’s medical devices provide a critical bridge in wound healing and tissue regeneration –a resorbable injectable nano-scale scaffold to accelerate ingrowth of normal local tissue.
Abraxis Oncology® is the proprietary pharmaceuticals division of Abraxis BioScience, LLC, an integrated global bio-pharmaceutical company. Abraxis Oncology® is dedicated to the discovery and development of novel cancer therapies that target tumor biological pathways. Our focus is to challenge current standards and develop next-generation therapies that revolutionize the treatment of cancer.